This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

9 Biotech Penny Stocks to Buy

By Louis Navellier of InvestorPlace

Penny stock investments in the biotech sector abound right now after the recent market turmoil this summer. Healthcare and biotech penny stocks can be volatile, particularly those drug manufacturers that are not yet profitable and are waiting on an important FDA approval notice. But these stocks can be very good investments if you buy at the right time.

My quantitative screens show that a number of biotech penny stocks -- that is, cheap healthcare companies trading for less than $3 a share -- have big upside potential for September as volume picks up on Wall Street. Here are nine top penny stocks in the biotech sector to consider.

1. Athersys Inc. (ATHX)

Market Cap: $49.21 million

Athersys (ATHX - Get Report) is a biopharmaceutical company engaged in the discovery and development of therapeutic products and is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness. Shares of ATHX have risen significantly in the past year, gaining 157% and both meeting and exceeding analyst estimates so far in 2010.

2. Catalyst Pharmaceutical Partners (CPRX)

Market Cap: $20.78 million

Catalyst Pharmaceutical Partners (CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting central nervous system diseases with a focus on the treatment of addiction and epilepsy. CPRX shares are up 70% year-to-date and growth potential seems promising for this small cap drug maker.

3. Rexahn Pharmaceuticals (RNN)

Market Cap: $100.66 million

Rexahn Pharmaceuticals (RNN) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system in patients. Rexahn's three clinical stage drug candidates are Archexin, Serdaxin and Zoraxel. With RNN stock up 78% since the start of the year, shareholders may want to keep their eye on this stock and its positive track record for beating EPS estimates.

4. Inhibitex (INHX)

Market Cap: 93.2 million

Inhibitex (INHX) is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent and treat serious infections. This small-cap pharma stock is showing some good growth potential with year-to-date performance at +63%. In addition to shares surging this summer, prospective investors should note that INHX has beat earnings estimates for three of the past four quarters.

5. Cyclacel Pharmaceuticals (CYCC)

Market Cap: $53.58 million

Cyclacel Pharmaceuticals (CYCC - Get Report) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. With shares up 40% since January, CYCC could end up being a bargain at its current price of around $1.45 if it can manage to swing into another uptrend.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ATHX $1.06 -3.60%
CYCC $0.70 -2.10%
CPRX $2.72 0.18%
CUR $1.12 1.80%
LUNA $1.07 -0.93%


Chart of I:DJI
DOW 17,821.38 +101.46 0.57%
S&P 500 2,091.28 +10.87 0.52%
NASDAQ 5,130.8320 +22.1660 0.43%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs